Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.

[1]  B. O'brien,et al.  Cost–effectiveness analysis for multinational clinical trials , 2005, Statistics in medicine.

[2]  B. O'brien,et al.  Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. , 2005, Health economics.

[3]  A. Gnanasakthy,et al.  Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2004, American heart journal.

[4]  Andrew R Willan,et al.  Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.

[5]  Michael Drummond,et al.  Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.

[6]  Y. R. Wang,et al.  High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. , 2003, The American journal of managed care.

[7]  Amiram Gafni,et al.  Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. , 2003, Health policy.

[8]  S. Yusuf,et al.  Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003 .

[9]  Ruth Brown,et al.  Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. , 2003, The Canadian journal of cardiology.

[10]  M. Lens,et al.  Economic evaluation in evidence-based practice , 2002, Expert opinion on pharmacotherapy.

[11]  Robert M Califf,et al.  Lessons learned from recent cardiovascular clinical trials: Part II. , 2002, Circulation.

[12]  T. Kahan,et al.  The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study , 2002, Journal of internal medicine.

[13]  H. Glick,et al.  PMI10 DANCING WITH THE DEVIL: THE IMPORTANCE OF SUB-GROUP ANALYSIS IN ECONOMIC EVALUATION , 2002 .

[14]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[15]  M A Koopmanschap,et al.  Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.

[16]  R. Califf,et al.  International differences in treatment effects in cardiovascular clinical trials. , 2001, American heart journal.

[17]  P A Poole-Wilson,et al.  Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study , 2000, European journal of heart failure.

[18]  A A Tsiatis,et al.  Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.

[19]  R. Califf,et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.

[20]  P. Pattynama,et al.  International differences in health care costs in Europe and the United States: Do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism? , 1999, European Radiology.

[21]  W. Weintraub,et al.  Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. , 1999, Journal of the American College of Cardiology.

[22]  M. Rich,et al.  The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure , 1999, Cardiology.

[23]  H. Dargie,et al.  The Cardiac Insufficiency Bisoprolol Study II , 1999, The Lancet.

[24]  M. Tavakoli,et al.  A COST MINIMISATION ANALYSIS OF CARDIAC FAILURE TREATMENT IN THE UK USING CIBIS TRIAL DATA , 1999, International journal of clinical practice.

[25]  H A Glick,et al.  The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. , 1998, American journal of hypertension.

[26]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[27]  P Carlsson,et al.  Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.

[28]  R. Willke,et al.  Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.

[29]  P. Lechat,et al.  A Cost-Minimization of Heart Failure Therapy with Bisoprolol in the French Setting: An Analysis from CIBIS Trial Data , 1998, Cardiovascular Drugs and Therapy.

[30]  M. Weinstein,et al.  Economic Evaluation Alongside Multinational Clinical Trials: Study Considerations for GUSTO iib , 1997, International Journal of Technology Assessment in Health Care.

[31]  Andrew M. Jones,et al.  Multilevel models and health economics. , 1997, Health economics.

[32]  R. Simes,et al.  Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease. , 1997, Controlled clinical trials.

[33]  S. Ball,et al.  Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. , 1997, PharmacoEconomics.

[34]  K. Schulman,et al.  Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation , 1996, International Journal of Technology Assessment in Health Care.

[35]  H Wedel,et al.  Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.

[36]  G. Thorgeirsson,et al.  Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.

[37]  B. Kinosian,et al.  Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. , 1995, Journal of cardiac failure.

[38]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[39]  M. Drummond,et al.  Issues in the Cross-National Assessment of Health Technology , 1992, International Journal of Technology Assessment in Health Care.

[40]  B Kinosian,et al.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. , 1991, The New England journal of medicine.

[41]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[42]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[43]  D L Sackett,et al.  Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. , 1981, The New England journal of medicine.

[44]  H. Glick,et al.  Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure , 2004, Cardiovascular Drugs and Therapy.

[45]  P. Erne,et al.  The Economic Efficiency of Amlodipine in the Treatment of Coronary Atherosclerosis—An Analysis Based on the PREVENT Study , 2004, Cardiovascular Drugs and Therapy.

[46]  J. Darbà,et al.  Cost data assessment in multinational economic evaluations: some theory and review of published studies. , 2003, Applied health economics and health policy.

[47]  J Hutton,et al.  Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2002, European heart journal.